EUR 3.5
(2.04%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 105.92 Million EUR | -12.47% |
2022 | 121.01 Million EUR | -25.59% |
2021 | 162.62 Million EUR | -24.28% |
2020 | 214.77 Million EUR | -4.88% |
2019 | 225.78 Million EUR | 8.27% |
2018 | 208.53 Million EUR | 10.36% |
2017 | 188.95 Million EUR | 706.91% |
2016 | 23.41 Million EUR | 69.17% |
2015 | 13.84 Million EUR | -13.15% |
2014 | 15.93 Million EUR | 5.84% |
2013 | 15.05 Million EUR | -10.09% |
2012 | 16.74 Million EUR | -31.97% |
2011 | 24.61 Million EUR | 7.05% |
2010 | 22.99 Million EUR | 0.39% |
2009 | 22.9 Million EUR | -2.98% |
2008 | 23.61 Million EUR | 59.04% |
2007 | 14.84 Million EUR | -19.64% |
2006 | 18.47 Million EUR | 5.88% |
2005 | 17.44 Million EUR | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q2 | 97.41 Million EUR | 0.0% |
2023 FY | 105.92 Million EUR | -12.47% |
2023 Q2 | 119.38 Million EUR | 0.0% |
2023 Q4 | 105.92 Million EUR | 0.0% |
2022 Q2 | 127.88 Million EUR | 0.0% |
2022 FY | 121.01 Million EUR | -25.59% |
2022 Q4 | 121.01 Million EUR | 0.0% |
2021 Q4 | 162.62 Million EUR | 0.0% |
2021 FY | 162.62 Million EUR | -24.28% |
2021 Q2 | 101.14 Million EUR | 0.0% |
2020 Q4 | 214.77 Million EUR | 0.0% |
2020 Q2 | 224.81 Million EUR | 0.0% |
2020 FY | 214.77 Million EUR | -4.88% |
2019 Q4 | 225.78 Million EUR | 0.0% |
2019 Q2 | 227.66 Million EUR | 0.0% |
2019 FY | 225.78 Million EUR | 8.27% |
2018 Q4 | 208.53 Million EUR | 0.0% |
2018 Q2 | 193.63 Million EUR | 0.0% |
2018 FY | 208.53 Million EUR | 10.36% |
2017 Q4 | 188.95 Million EUR | 0.0% |
2017 FY | 188.95 Million EUR | 706.91% |
2017 Q2 | 27.11 Million EUR | 0.0% |
2016 Q4 | 23.41 Million EUR | 0.0% |
2016 FY | 23.41 Million EUR | 69.17% |
2016 Q2 | 17.06 Million EUR | 0.0% |
2015 Q4 | 13.84 Million EUR | 0.0% |
2015 FY | 13.84 Million EUR | -13.15% |
2015 Q2 | 13.33 Million EUR | 0.0% |
2014 Q4 | 15.93 Million EUR | 0.0% |
2014 Q2 | 19.73 Million EUR | 0.0% |
2014 FY | 15.93 Million EUR | 5.84% |
2013 Q4 | 15.05 Million EUR | 0.0% |
2013 Q2 | 16.28 Million EUR | 0.0% |
2013 FY | 15.05 Million EUR | -10.09% |
2012 Q4 | 16.74 Million EUR | 0.0% |
2012 Q2 | 23.24 Million EUR | 0.0% |
2012 FY | 16.74 Million EUR | -31.97% |
2011 Q2 | 22.88 Million EUR | 0.0% |
2011 Q4 | 24.61 Million EUR | 0.0% |
2011 FY | 24.61 Million EUR | 7.05% |
2010 FY | 22.99 Million EUR | 0.39% |
2010 Q4 | 22.99 Million EUR | 0.0% |
2010 Q2 | 22.4 Million EUR | 0.0% |
2009 FY | 22.9 Million EUR | -2.98% |
2009 Q4 | 22.9 Million EUR | 0.0% |
2009 Q2 | 22.92 Million EUR | 0.0% |
2008 FY | 23.61 Million EUR | 59.04% |
2007 FY | 14.84 Million EUR | -19.64% |
2006 FY | 18.47 Million EUR | 5.88% |
2005 FY | 17.44 Million EUR | 0.0% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
ABIONYX Pharma SA | 6.91 Million EUR | -1432.422% |
ABIVAX Société Anonyme | 131.05 Million EUR | 19.176% |
Adocia SA | 31.87 Million EUR | -232.353% |
Aelis Farma SA | 13.08 Million EUR | -709.794% |
Biophytis S.A. | 15.84 Million EUR | -568.313% |
Advicenne S.A. | 24.37 Million EUR | -334.512% |
genOway Société anonyme | 14.45 Million EUR | -632.535% |
IntegraGen SA | 5.97 Million EUR | -1671.314% |
Medesis Pharma S.A. | 6.42 Million EUR | -1548.272% |
Neovacs S.A. | 3.71 Million EUR | -2753.38% |
NFL Biosciences SA | 3.62 Million EUR | -2825.443% |
Plant Advanced Technologies SA | 6.78 Million EUR | -1461.715% |
Quantum Genomics Société Anonyme | 3.31 Million EUR | -3099.927% |
Sensorion SA | 13.22 Million EUR | -700.778% |
Theranexus Société Anonyme | 5.01 Million EUR | -2011.583% |
TME Pharma N.V. | 2.78 Million EUR | -3703.268% |
Valbiotis SA | 13.7 Million EUR | -672.695% |
TheraVet SA | 1.48 Million EUR | -7032.761% |
Valerio Therapeutics Société anonyme | 20.46 Million EUR | -417.496% |
argenx SE | 402.79 Million EUR | 73.704% |
BioSenic S.A. | 32.26 Million EUR | -228.295% |
Celyad Oncology SA | 9.97 Million EUR | -961.545% |
DBV Technologies S.A. | 38.74 Million USD | -173.378% |
Galapagos NV | 1.56 Billion EUR | 93.218% |
GeNeuro SA | 20.13 Million EUR | -425.926% |
Hyloris Pharmaceuticals SA | 8.61 Million EUR | -1129.923% |
Innate Pharma S.A. | 132.29 Million EUR | 19.934% |
Inventiva S.A. | 101.59 Million EUR | -4.26% |
MaaT Pharma SA | 22.46 Million EUR | -371.493% |
MedinCell S.A. | 77.77 Million EUR | -36.198% |
Nanobiotix S.A. | 95.74 Million EUR | -10.634% |
Onward Medical N.V. | 25.69 Million EUR | -312.176% |
Oryzon Genomics S.A. | 25.12 Million EUR | -321.568% |
OSE Immunotherapeutics SA | 59.07 Million EUR | -79.287% |
Oxurion NV | 19.73 Million EUR | -436.689% |
Pharming Group N.V. | 228.28 Million EUR | 53.601% |
Poxel S.A. | 53.9 Million EUR | -96.51% |
GenSight Biologics S.A. | 34.72 Million EUR | -205.011% |
Transgene SA | 26.51 Million EUR | -299.446% |
Financière de Tubize SA | 123.65 Million EUR | 14.338% |
UCB SA | 6.56 Billion EUR | 98.386% |
Valneva SE | 341.14 Million EUR | 68.951% |
Vivoryon Therapeutics N.V. | 4.54 Million EUR | -2229.47% |